Journal articles on the topic 'N-022'
To see the other types of publications on this topic, follow the link: N-022.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'N-022.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Bridge, Erica, Simron Singh, Amanda Murdoch, Mindaugas Mozuraitis, Brett Nicholls, and Lesley Moody. "Examining patient and visit characteristics associated with the cancer patient experience." Journal of Clinical Oncology 37, no. 27_suppl (September 20, 2019): 204. http://dx.doi.org/10.1200/jco.2019.37.27_suppl.204.
Full textAbstract:
204 Background: Your Voice Matters (YVM) is a 28-item patient experience survey for adult cancer outpatients undergoing treatment in Ontario.The purpose was to examine patient and visit characteristics associated with YVM responses. Methods: YVM was administered to eligible patients (n=8,704) at 14 centres in 2017.Respondents answered items on a five-point Likert scale (4 or 5 = positive response). A multivariable logistic regression (MLR) was undertaken for each YVM item.Variables (reference group) included: disease site (heamatology), age group (65+), sex (female), rurality (urban), last visit type (consult), income quintile(highest) and immigration tercile (lowest). Significant results ( p<.05) vary by MLR model. Therefore a p-value range is provided for all significant variables for all MLR models. Results: Patients were more likely to have a less positive experience if they had central nervous system ( p =.000-.013), gastrointestinal ( p =.004-.026), head and neck ( p =.002-.025), or lung cancer ( p =.017-.049); were between the ages of 18-39 years ( p = <.0001-.048); were female ( p =.0001-.022); received chemotherapy( p =.0001-.047); lived in a rural location ( p =.042); from a mid-( p =.027-.045) and mid-high income quartile ( p =.021); and in the high- ( p =.002-.043) and middle-immigrant terciles ( p =.028-.047), when compared to the reference group. Patient were more likely to have a more positive experience if they had skin cancer ( p =.004-.032); were between the ages of 40-64 years ( p =.003-.033); receiving radiation ( p =.0001-.041) or a minor procedure ( p =.015); and were from the mid-low ( p =.003-.042) and low income quartile ( p =.001-.032), when compared to the reference group. Conclusions: The cancer patient experience varies by patient and visit characteristics. Future initiatives should examine these characteristics to better understand their populations to create a more tailored approaches to cancer care.
2
Myroslava I, Vovk, Pukach Petro Ya, and Prykarpatski Anatolij K. "A remark on a perturbed Benjamin-Bona-Mahony type equation and its complete integrability." Annals of Mathematics and Physics 6, no. 1 (February 14, 2023): 021–25. http://dx.doi.org/10.17352/amp.000071.
Full textAbstract:
vv 022 Citation: Vovk MI, Pukach PY, Prykarpatski AK (2023) A remark on a perturbed Benjamin-Bona-Mahony type equation and its complete integrability. Ann Math Phys 6(1): 021-025. DOI: https://dx.doi.org/10.17352/amp.000071 https://dx.doi.org/10.17352/ampDOI: M A T H E M A T I C S A N D P H Y S I C S G R O U P 2689-7636ISSN: ABSTRACT IN THE LETTER, WE STUDY A PERTURBED BENJAMIN-BONA-MAHONY NONLINEAR EQUATION, WHICH WAS DERIVED FOR DESCRIBING SHALLOW WATER WAVES AND POSSESSING A RICH LIE SYMMETRY STRUCTURE. BASED ON THE GRADIENT-HOLONOMIC INTEGRABILITY CHECKING SCHEME APPLIED TO THIS EQUATION, WE HAVE ANALYTICALLY CONSTRUCTED ITS INFINITE HIERARCHY OF CONSERVATION LAWS, DERIVED TWO COMPATIBLE POISSON STRUCTURE AND STATED ITS COMPLETE INTEGRABILITY.
3
Hayhoe, Richard P. G., Marleen A. H. Lentjes, Angela A. Mulligan, Robert N. Luben, Kay-Tee Khaw, and Ailsa A. Welch. "Carotenoid dietary intakes and plasma concentrations are associated with heel bone ultrasound attenuation and osteoporotic fracture risk in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohort." British Journal of Nutrition 117, no. 10 (May 28, 2017): 1439–53. http://dx.doi.org/10.1017/s0007114517001180.
Full textAbstract:
AbstractCarotenoids are found in abundance in fruit and vegetables, and may be involved in the positive association of these foods with bone health. This study aimed to explore the associations of dietary carotenoid intakes and plasma concentrations with bone density status and osteoporotic fracture risk in a European population. Cross-sectional analyses (n 14 803) of bone density status, using calcaneal broadband ultrasound attenuation (BUA) and longitudinal analyses (n 25 439) of fracture cases were conducted on data from the prospective European Prospective Investigation into Cancer and Nutrition-Norfolk cohort of middle-aged and older men and women. Health and lifestyle questionnaires were completed, and dietary nutrient intakes were derived from 7-d food diaries. Multiple regression demonstrated significant positive trends in BUA for women across quintiles of dietary α-carotene intake (P=0·029), β-carotene intake (P=0·003), β-cryptoxanthin intake (P=0·031), combined lutein and zeaxanthin intake (P=0·010) and lycopene intake (P=0·005). No significant trends across plasma carotenoid concentration quintiles were apparent (n 4570). The Prentice-weighted Cox regression showed no trends in fracture risk across dietary carotenoid intake quintiles (mean follow-up time 12·5 years), except for a lower risk for wrist fracture in women with higher lutein and zeaxanthin intake (P=0·022); nevertheless, inter-quintile differences in fracture risk were found for both sexes. Analysis of plasma carotenoid data (mean follow-up time 11·9 years) showed lower hip fracture risk in men across higher plasma α-carotene (P=0·026) and β-carotene (P=0·027) quintiles. This study provides novel evidence that dietary carotenoid intake is relevant to bone health in men and women, demonstrating that associations with bone density status and fracture risk exist for dietary intake of specific carotenoids and their plasma concentrations.
4
Ju, Hyerim, Shailashree Pachhapure, Amila Mufida, Aryun Kim, David R. Elmaleh, Sungwoon Choi, and Byeong-Churl Jang. "2-Aryl Propionic Acid Amide Modification of Naproxen and Ibuprofen Dimers for Anti-neuroinflammatory Activity in BV2 mouse Microglial Cells." Keimyung Medical Journal 41, no. 2 (December 15, 2022): 56–66. http://dx.doi.org/10.46308/kmj.2022.00199.
Full textAbstract:
Inflammation is a common link in the pathophysiology of many neurological illnesses, including Alzheimer’s disease. Activated glial cells contribute to neuroinflammation by producing pro-inflammatory mediators. Naproxen and ibuprofen are nonsteroidal anti-inflammatory drugs with 2-aryl(s) propionic acid as a common pharmacophore. Here we designed a small series of naproxen and ibuprofen amide dimers and tested their effects on the expression of inducible nitric oxide synthase (iNOS), a neuroinflammatory enzyme in lipopolysaccharide (LPS)-stimulated BV2 mouse microglial cells. Of note, treatment with CNU 019, 020, 021, 023, 024, and 027 at 10 M markedly inhibited the LPS-induced iNOS expression in BV2 cells. CNU 024 was tested further at different concentrations to regulate the LPS-induced iNOS expression in BV2 cells. Treatment with CNU 024 at 5, 10, or 20 M dose-dependently suppressed the LPS-induced iNOS protein and mRNA expression levels in BV2 cells, in which maximal inhibition was seen at 20 M. CNU 024 treatment at doses tested further led to a concentration-dependent inhibition of the LPS-induced phosphorylation (activation) of p38 mitogen-activated protein kinase (MAPK) without influencing its total protein expression in BV2 cells, but it did not affect the LPS-induced activation of c-jun N-terminal kinase-1/2 and extracellular signal-regulated kinases-1/2 in these cells. In summary, our results demonstrate that CNU 024 inhibits the LPS-induced iNOS expression in BV2 cells, partly mediated by the inhibition of p38 MAPK. This work shows that CNU 024 could be a valuable ligand for further development as a potential drug candidate for treating neuroinflammatory pathologies.
5
Tristão Parra, Maíra, Naghmeh Esmeaeli, Jordan Kohn, Brook L. Henry, Stephen Klagholz, Shamini Jain, Christopher Pruitt, Daniel Vicario, Wayne Jonas, and Paul J. Mills. "Greater Well-Being in More Physically Active Cancer Patients Who Are Enrolled in Supportive Care Services." Integrative Cancer Therapies 19 (January 2020): 153473542092143. http://dx.doi.org/10.1177/1534735420921439.
Full textAbstract:
Background: Cancers are one of the leading causes of mortality worldwide. Cancer patients are increasingly seeking integrative care clinics to promote their health and well-being during and after treatment. Aim: To examine relationships between physical activity (PA) and quality of life (QoL) in a sample of cancer patients enrolling in integrative care in a supportive care clinic. Also, to explore circulating inflammatory biomarkers and heart rate variability (HRV) in relationship to PA and QoL. Methods: A cross-sectional design of adult patients who sought care in the InspireHealth clinic, Vancouver, British Columbia, Canada. Patients with complete PA data (n = 118) answered psychosocial questionnaires, provided blood samples, and received HRV recordings before enrollment. Patients were stratified into “less” versus “more” active groups according to PA guidelines (150 minutes of moderate or 75 minutes of vigorous PA or an equivalent combination). Results: Breast (33.1%) and prostate (10.2%) cancers were the most prevalent primary diagnoses. Patients engaging in more PA reported better physical ( U = 1265.5, P = .013), functional ( U = 1306.5, P = .024), and general QoL ( U = 1341, P = .039), less fatigue ( U = 1268, P = .014), fewer physical cancer-related symptoms ( U = 2.338, P = .021), and less general distress ( U = 2.061, P = .021). Between PA groups, type of primary cancer diagnosis differed (χ2 = 41.79, P = .014), while stages of cancer did not (χ2 = 3.95, P = .412). Fewer patients reported depressed mood within the more active group (χ2 = 6.131, P = .047). More active patients were also less likely to have ever used tobacco (χ2 = 7.41, P = .025) and used fewer nutritional supplements (χ2 = 39.74, P ≤ .001). An inflammatory biomarker index was negatively correlated with vigorous PA ( rs = −0.215, P = .022). Multivariable linear regression ( R2 = 0.71) revealed that age (β = 0.22; P = .001), fatigue (β = −0.43; P ≤ .001), anxiety (β = −0.14; P = .048), and social support (β = 0.38; P = .001) were significant correlates of QoL.
6
Carré, Typhanie, Caroline Gaudy-Marqueste, Frédérique Albarel, Sandrine Monestier, Stéphanie Mallet, Thierry Brue, Marie-Aleth Richard, and Jean Jacques Grob. "Ipilimumab-induced hypophysitis in melanoma patients." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 8568. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.8568.
Full textAbstract:
8568 Background: Ipilimumab (Ipi) is a human monoclonal antibody directed against cytotoxic T-lymphocyte antigene-4 (CTLA-4) recently approved for the treatment of metastatic melanoma (MM) and currently under investigation in the adjuvant setting. Methods: Retrospective analysis of patients treated with ipi between June 2006 and September 2011 in our department in Marseille. As some patients are still blinded in trials, the exact number of patient under ipi is unknown. We present a minimal percentage (>%) assuming that the 120 patients received ipi. Results: A total of 120 patients were treated: 76 stages IV MM, from which 16 in the BMS clinical trials (CA184-022, -024, and-025 and MDX 010-20) and 44 stages III MM (in the BMS CA184-029 trial). Stage IV MM were administered 0.3, 3 or 10mg/kg IV dosage, while stages III MM were randomly assigned to receive 10 mg/ kg or placebo (1:1 ratio). Hypophysitis was diagnosed in 12 patients (>10%): 2/76 patients with stage IV MM (>2. 6 %) and 10/44 patients with stage III MM (>22.7). Diagnosis was performed at the 1st, 3rd and 4th administration in respectively 2 (1.6%), 6 (50%) and 4 patients (33.3%). Clinical symptoms included headaches (n=11; 91.6%), asthenia (n=7; 58.3%) and decreased libido (n=2; 1.6%). Adrenal, thyroidal and gonadal axis were affected in respectively 6 (50%), 9 (75%) and 7 patients (58.3%). MRI changes were observed in 7 patients (58.3%): pituitary swelling in 5 patients (41.6%) and heterogeneous enhancement in 4 patients (33.3%) including 2 patients with normal biology. Corticosteroids supplementation was required in 11 patients and thyroidian supplementation in 4 patients. Clinical symptoms regressed within one week in 8 patients (66.6%). Conclusions: Ipi-induced hypophysitis is detectable only if clinicians are aware of these unspecific signs. Only MRI can make diagnosis in some patients without clinical and/or biological signs. Our data suggest that it develops especially for 10mg/kg dosage, after the third administration, and that the rate could be higher in patients with a normal immune system (adjuvant treatment), than in metastatic ones. Hormonal supplementation usually controls the disease.
7
O’Brien, Eileen C., Goiuri Alberdi, Aisling A. Geraghty, and Fionnuala M. McAuliffe. "Lower education predicts poor response to dietary intervention in pregnancy, regardless of neighbourhood affluence: secondary analysis from the ROLO randomised control trial." Public Health Nutrition 20, no. 16 (August 15, 2017): 2959–69. http://dx.doi.org/10.1017/s1368980017001951.
Full textAbstract:
AbstractObjectiveTo determine if response to a low glycaemic index (GI) dietary intervention, measured by changes in dietary intake and gestational weight gain, differed across women of varying socio-economic status (SES).DesignSecondary data analysis of the ROLO randomised control trial. The intervention consisted of a two-hour low-GI dietary education session in early pregnancy. Change in GI was measured using 3 d food diaries pre- and post-intervention. Gestational weight gain was categorised as per the 2009 Institute of Medicine guidelines. SES was measured using education and neighbourhood deprivation.SettingThe National Maternity Hospital, Dublin, Ireland.SubjectsWomen (n 625) recruited to the ROLO randomised control trial.ResultsThe intervention significantly reduced GI and excess gestational weight gain (EGWG) among women with third level education residing in both disadvantaged (GI, mean (sd), intervention v. control: −3·30 (5·15) v. −0·32 (4·22), P=0·024; EGWG, n (%), intervention v. control: 7 (33·6) v. 22 (67·9); P=0·022) and advantaged areas (GI: −1·13 (3·88) v. 0·06 (3·75), P=0·020; EGWG: 41 (34·1) v. 58 (52·6); P=0·006). Neither GI nor gestational weight gain differed between the intervention and control group among women with less than third level education, regardless of neighbourhood deprivation.ConclusionsA single dietary education session was not effective in reducing GI or gestational weight gain among less educated women. Multifaceted, appropriate and practical approaches are required in pregnancy interventions to improve pregnancy outcomes for less educated women.
8
Sharara-Chami, Rana, Zavi Lakissian, Randa Farha, Hani Tamim, and Nicholas Batley. "In-situ simulation-based intervention for enhancing teamwork in the emergency department." BMJ Simulation and Technology Enhanced Learning 6, no. 3 (August 19, 2019): 175–77. http://dx.doi.org/10.1136/bmjstel-2019-000473.
Full textAbstract:
Simulation-based learning activities in the emergency department (ED) improve communication and teamwork and familiarise personnel with existing protocols. The authors’ objective was to develop standardised in-situ simulations and to assess their effects on team performance during simulated patient care. The study was a prospective, single-centre pre-in-situ and post-in-situ simulation-based intervention in the ED of an academic hospital between March 2017 and February 2018. Teams of three to five participants (n=46) were in two simulation interventions 2 weeks apart; each simulation was followed by debriefing with good judgement. The adapted Simulation Team Assessment Tool (STAT) Score was the primary measure for team performance. Skills are measured on a scale of 2–0 based on the complete and timely performance of tasks for a total (adapted) score of 171. Overall STAT scores improved significantly between simulations I (60.5 (28.3)) and II (81.1 (24.6)), p=029; notably in airway and teamwork domains, p=022 and p=023, respectively. A sub-analysis showed that participants performed significantly better when treating adult versus paediatric simulated patients (87.9 (20.1)), p=003, particularly in teamwork, p=01. The study yielded statistically significant improvement in clinical management, teamwork and resource management skills among ED personnel.
9
Galvão, Daniel A., Dennis R. Taaffe, Nigel Spry, David Joseph, and Robert U. Newton. "Combined Resistance and Aerobic Exercise Program Reverses Muscle Loss in Men Undergoing Androgen Suppression Therapy for Prostate Cancer Without Bone Metastases: A Randomized Controlled Trial." Journal of Clinical Oncology 28, no. 2 (January 10, 2010): 340–47. http://dx.doi.org/10.1200/jco.2009.23.2488.
Full textAbstract:
Purpose Androgen suppression therapy (AST) results in musculoskeletal toxicity that reduces physical function and quality of life. This study examined the impact of a combined resistance and aerobic exercise program as a countermeasure to these AST-related toxicities. Patients and Methods Between 2007 and 2008, 57 patients with prostate cancer undergoing AST (commenced > 2 months prior) were randomly assigned to a program of resistance and aerobic exercise (n = 29) or usual care (n = 28) for 12 weeks. Primary end points were whole body and regional lean mass. Secondary end points were muscle strength and function, cardiorespiratory capacity, blood biomarkers, and quality of life. Results Analysis of covariance was used to compare outcomes for groups at 12 weeks adjusted for baseline values and potential confounders. Patients undergoing exercise showed an increase in lean mass compared with usual care (total body, P = .047; upper limb, P < .001; lower limb, P = .019) and similarly better muscle strength (P < .01), 6-meter walk time (P = .024), and 6-meter backward walk time (P = .039). Exercise also improved several aspects of quality of life including general health (P = .022) and reduced fatigue (P = .021) and decreased levels of C-reactive protein (P = .008). There were no adverse events during the testing or exercise intervention program. Conclusion A relatively brief exposure to exercise significantly improved muscle mass, strength, physical function, and balance in hypogonadal men compared with normal care. The exercise regimen was well tolerated and could be recommended for patients undergoing AST as an effective countermeasure to these common treatment-related adverse effects.
10
Ohanian, Maro, Hagop M. Kantarjian, Farhad Ravandi, Gautam Borthakur, Guillermo Garcia-Manero, Michael Andreeff, Elias Jabbour, et al. "Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)." Blood 126, no. 23 (December 3, 2015): 3801. http://dx.doi.org/10.1182/blood.v126.23.3801.3801.
Full textAbstract:
Abstract Background: Essential to cancer cell signaling, the growth receptor bound protein-2 (Grb-2) is evolutionarily conserved and utilized by oncogenic tyrosine kinases including Bcr-Abl to activate Ras, ERK, and AKT. BP-100-1.01is a neutrally-charged, liposome-incorporated antisense designed to inhibit Grb-2 expression. Aim: To define the safety, maximum tolerated dose (MTD), optimal biologically active dose, pharmacokinetics and anti-leukemia activity of BP-100-1.01 in patients (pts) with hematologic malignancies. Methods: This is a standard 3+3 phase I dose-finding study in pts with relapsed or refractory acute myeloid leukemia (AML), chronic myeloid leukemia in blast phase (CML-BP), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). The starting dose was 5 mg/m2 twice weekly, IV over 2-3 hours for 28 days. Dose escalation proceeded through 5, 10, 20, 40, 60, and 90 mg/m2.Uponcompletion of single agent phase 1, combination of cytarabine 20 mg SubQ BID x 10 days + 60 mg/m2 of BP-100-1.01 was studied (Cohort 1B). Flow cytometric analysis was performed on peripheral blood samples from cohorts 3, 4, 5, 6 and 1B collected at baseline, on day 15 and at end-of-treatment (EOT). Fluorescent-labeled antibodies specific for Grb-2 or phosphorylated Erk (pErk) were utilized to determine Grb-2 protein levels and pErk levels in CD33-expressing cells. Results: A total of33 pts were included (13 in Cohort 1, 6 in Cohort 2, 3 each in Cohorts 3, 4, 5, and 4 in cohort 6). One patient has been treated in cohort 1B. The median age was 64 yrs (range, 32-89) and diagnoses were AML (n=24), CML-BP (n=5) and MDS (n=4). The median number of prior therapies was 4 (range, 1- 8). Of 33 pts, 21 were evaluable and 11 failed completion of a full 28-Day cycle due to disease progression (with no toxicity) and were replaced, per protocol. Only one pt (treated at 5 mg/m2) experienced dose limiting toxicity (DLT), grade 3 mucositis and hand-foot syndrome, while receiving concurrent hydroxyurea for proliferative CML-BP. The patient had a previous history of hydroxyurea-induced mucositis. Being the first patient to receive BP-100-1.01, these toxicities were considered possibly related to BP-100-1.01. The cohort was expanded to a total of 6 pts. No other DLTs have been noted in any pt. Among 21 evaluable pts, 11 experienced at least a 50% reduction in peripheral or bone marrow blasts from baseline. Additionally 2 pts with improvement in leukemia cutis lesions received 1 cycle each. Furthermore, 6 pts demonstrated transient improvement (n=3) and/or stable disease (n=3). Among the 21 evaluable pts, a median of 1 cycle was administered (1-5): Four pts received 2 cycles, 3 pts received 5 cycles, and all others received 1 cycle. Notably one pt (treated at 5 mg/m2)with CML-BP showed a significant reduction in blasts from 81% to 5%. Due to leptomeningeal disease progression therapy was discontinued before a full cycle. The 1st patient treated in cohort 1B achieved CR after 1 cycle. The patient did not experience any DLTs, but came off study due to failure to thrive in the context of dementia. The levels of Grb-2 and pErk proteins were indicated by their respective median fluorescent signals and are shown in the table. Median fluorescent signals of Grb-2 and pErk on days 15 and EOT were compared to baseline. On day 15 Grb-2 levels decreased by >25% in 7 out of 12 samples tested, and pErk levels by >25% in 6 out of 12 samples. The average decrease in Grb-2 levels was 61% (range: 47 to 85%) and in pErk levels 52% (range: 28 to 82%). On the last measured sample (EOT or day 22), BP-100-1.01 decreased >25% Grb-2 levels in 11 out of 13 samples, and >25% pErk levels in 7 out of 13 samples. The average decrease in Grb-2 levels was 49% (range: 28 to 91%) and in pErk levels was 52% (range: 27 to 91%). Table 1. Patient Number Grb-2 decrease (Day 15) pErk decrease (Day 15) Grb-2 decrease (Day 22 or EOT) pErk decrease (Day 22 or EOT) 022 0 0 57 0 023 0 3 28 45 024 56 28 47 35 025 63 82 54 91 026 47 0 0 0 027 NS NS 34 27 028 0 0 30 54 029 57 51 65a 0a 030 54 55 43 47 031 0 0 0 0 032 85 54 91 63 033 6 13 53 2 034 63 42 40 0 NS = no sample collected aFewer cells were used in the analysis of this sample than other samples, because this sample had less cells than other samples Conclusions: BP-100-1.01, at dose range 5 mg/m2 to 90 mg/m2 is well tolerated with no MTD yet identified. There is suggestion of Grb-2 target protein down-regulation, and possible anti-leukemia activity. Disclosures Konopleva: Novartis: Research Funding; AbbVie: Research Funding; Stemline: Research Funding; Calithera: Research Funding; Threshold: Research Funding. Tari:Bopath Holdings: Employment. Cortes:BerGenBio AS: Research Funding; Teva: Research Funding; Novartis: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Ariad: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Astellas: Consultancy, Research Funding; Ambit: Consultancy, Research Funding; Arog: Research Funding; Celator: Research Funding; Jenssen: Consultancy.
11
Berman, D. M., J. Wolchok, J. Weber, O. Hamid, S. O'Day, and S. D. Chasalow. "Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 3020. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.3020.
Full textAbstract:
3020 Background: Ipilimumab, an anti-CTLA-4 monoclonal antibody, induces durable survival benefits in advanced melanoma pts. Peripheral ALC from routine safety labs were collected from 533 pts with unresectable stage III/IV malignant melanoma treated with ipilimumab 0.3, 3, or 10 mg/kg (recommended dose) in 4 Phase II studies. Methods: Ipilimumab was given every 3 weeks (Q3W) x 4; eligible pts could then continue to receive ipilimumab Q12W starting at Week 24. ALC was analyzed first in studies CA184007, 008, and 022 combined (ipilimumab 0.3, 3, or 10 mg/kg), and then prospectively analyzed for confirmation in study CA184004 (ipilimumab 3 or 10 mg/kg). Using the modified World Health Organization criteria, Response-evaluable pts (n = 444) were classified by clinical activity (complete or partial response, or stable disease ≥ 24 wks) or without clinical activity. Results: Across studies 007, 008, and 022, pts with clinical activity had a greater mean rate of ALC change (slope) than did pts without clinical activity (P = 0.0013); no pt with a negative ALC slope over the induction period had clinical activity (P = 0.0013) (Table). These associations were confirmed in 004; pts with benefit had a greater mean slope (P = 0.00042), and only 1 pt with a (slightly) negative ALC slope had clinical activity (Table). Over all pts (n = 533), the rate of ALC change was significantly associated with dose (007, 008, 022: P < 0.0001; 004: P = 0.0015). Conclusions: A higher rate of ALC change was associated with clinical activity in a pooled analysis of studies 007, 008, and 022 (n = 379). This was confirmed in study 004 (n = 65). A negative ALC slope was associated with a lack of clinical activity. In both analyses, the rate of change in ALC was dose-dependent, favoring 10 mg/kg. [Table: see text] [Table: see text]
12
Santoro, Bernardo. "Governo e Mercado." MISES: Interdisciplinary Journal of Philosophy, Law and Economics 1, no. 1 (February 21, 2018): 288–91. http://dx.doi.org/10.30800/mises.2013.v1.235.
Full text
13
Kataev, S. S., O. N. Dvorskaya, and M. A. Gofenberg. "Identification of cannabimimetics MDMB(N)-022 in urine using SPE AND GG-MS." Problems of Biological Medical and Pharmaceutical Chemistry 25, no. 1 (2022): 10–20. http://dx.doi.org/10.29296/25877313-2022-01-02.
Full text
14
McCarter, Helen, William Furlong, Anthony C. Whitton, David Feeny, Sonja DePauw, Andrew R. Willan, and Ronald D. Barr. "Health Status Measurements at Diagnosis As Predictors of Survival Among Adults With Brain Tumors." Journal of Clinical Oncology 24, no. 22 (August 1, 2006): 3636–43. http://dx.doi.org/10.1200/jco.2006.06.0137.
Full textAbstract:
Purpose The intent of this study was to determine whether baseline measures of functional capacity and performance could be used to predict survival in adults following the diagnosis of brain tumors. Patients and Methods Comprehensive health status and health-related quality of life (HRQL) were measured using the Health Utilities Index (HUI; McMaster University, Hamilton, Canada) system by a self-assessment questionnaire in a survey of 100 consecutive patients. The Karnofsky Performance Score (KPS) and Folstein's Mini-Mental State Examination (MMSE) scores were measured by a physician blinded to the HUI results. The patients were observed for up to 5 years to recorded dates of death. Results An HUI questionnaire was completed for 93% of the patients and 69% died within 5 years of assessment. The HUI revealed a burden of morbidity and complexity of disability that far exceeded that reported for the general population. KPS and MMSE correlated strongly with each other (r = 0.52; P < .001). A decrease of 0.1 units in HUI Mark 2 (HUI2) self-care single-attribute utility score was associated with an increased hazard of death of 30% (P = .023) for patients with low-grade tumors (n=25). For patients with high-grade tumors (n=56), a 10 unit decrease in the KPS, a 5 unit decrease in MMSE, and a 0.1 decrease in HUI Mark 3 (HUI3) speech and dexterity single-attribute scores were associated with an increased hazard of death of 20% (P = .022), 26% (P = .015), 36% (P = .021), and 18% (P = .035), respectively. Conclusion Scores derived from the measurement of HRQL following diagnosis can predict survival in adults with brain tumors.
15
Caperchione, Cristina M., Sean Stolp, Joan L. Bottorff, John L. Oliffe, Steven T. Johnson, Cherisse Seaton, Paul Sharp, et al. "Changes in Men’s Physical Activity and Healthy Eating Knowledge and Behavior as a Result of Program Exposure: Findings From the Workplace POWERPLAY Program." Journal of Physical Activity and Health 13, no. 12 (December 2016): 1364–71. http://dx.doi.org/10.1123/jpah.2016-0111.
Full textAbstract:
Background:The purpose of this study was to examine changes in physical activity and healthy eating knowledge and behaviors associated with the level of exposure to POWERPLAY, a men-centered workplace health promotion program.Methods:This study is based on a quasi-experimental prepost design. Using a computer assisted telephone interview survey, data regarding program exposure and physical activity and health eating knowledge and behaviors were collected from men (N = 103) in 4 workplaces.Results:Exposure scores were calculated and participants were categorized as having low (n = 54) or high exposure (n = 49) to POWERPLAY. Compared with the low exposure group, those reporting high exposure scored significantly higher on physical activity knowledge (F (1, 99) =14.17, P < .001, eta2 = .125) and health eating knowledge (F (1, 99) =14.37, P = .001, eta2 = .111). The high exposure group also reported significantly more minutes walked place to place (F (2, 206) = 3.91, P = .022, eta2 = .037) and on minutes walked for leisure (F (2, 230) = 3.08, P = .048, eta2 = .026).Conclusions:POWERPLAY shows significant promise as a workplace health promotion approach and may have an even greater impact when program exposure is augmented with environmental and policy changes.
16
Kim, Sung-Hyun, So-Jung Choi, Jinseon Lee, and Jhingook Kim. "Differential gene expression associated with the tropism between hepatic and pulmonary metastases in colorectal cancers." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e21062-e21062. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e21062.
Full textAbstract:
e21062 Background: In metastatic colorectal cancers tumor cells were already disseminated, prior to surgical resection of the primary tumors, but micrometastases remain dormant until proper colonization mechanisms are activated. Specific aims of this study are, 1) to examine the colonization pathways and genes newly activated in metastatic tumors by longitudinal pair-wise comparisons between primary-to-metastatic tumors and 2) to understand tropism between colon-to-liver and colon-to-lung metastases at gene expression level. Methods: Total 24 tumor samples were prepared as longitudinal pairs from 6 hepatic, and 6 pulmonary cases. In these samples mRNA levels were quantitatively determined for 215 genes that were previously reported to play roles in metastasis, cytokines signaling, or angiogenesis, as provided as RT2 Profiler TM PCR arrays (PAHS-022, 024, 028). Unsupervised hierarchical clustering of Ct values and heat map analyses of DCt values were carried out using web based data analysis program, and 17-gene tropism signature was selected for stratification of the hepatic and the pulmonary metastases. Results: Ct values of 23 duplicated genes and 5 house-keeping genes showed plate-to-plate correlation of 0.92. Unsupervised hierarchical clustering of the Ct values from the Metastasis Arrays revealed that the hepatic metastases were indistinguishable from the primary colorectal cancers (n=5/6), but the lung metastases were highly diversified (n=6/6). Cytokine Array data also showed the divergence of pulmonary metastases from the primary colorectal cancers (n=6/6). Heat map analyses of DCt values from the Metastasis Arrays identified 17-gene tropism signature that was sufficient not only to distinguish the liver and the lung metastases, but also reconstitute the clustering of primary tumors with the hepatic metastases. Conclusions: Intrinsic difference existed between the pulmonary and hepatic metastases of colorectal origins among the tested samples. 17-gene tropism signature was identified, and further genomic and clinical studies are in process to validate their potentials as therapeutic targets to treat pulmonary metastases of colorectal cancers.
17
Kim, Heejung, and So-Hi Kwon. "Effects of Handoff Education using Concept Mapping and PASS-BAR." Journal of Korean Academy of Fundamentals of Nursing 28, no. 1 (February 26, 2021): 1–10. http://dx.doi.org/10.7739/jkafn.2021.28.1.1.
Full textAbstract:
Purpose: The purpose of this study was to identify effects of Handoff Education using Concept mapping and PASS-BAR (HECPAR) on clinical reasoning competence, self-efficacy for handoff, and handoff performance of new nurses.Methods: Participants were randomly allocated into an experimental group (n=20) and control group (n=21). The experimental group received HECPAR which consisted of a one hour lecture, case based clinical practicum, and mentoring for a week. The control group received the usual informal handoffs education from senior nurses. Clinical reasoning competence, self-efficacy for handoff, and handoff performance were measured before and a week after HECPAR. Data were analyzed using Mann-Whitney U test, independent t-test, Fisher’s exact test, and chi-sqaure test. Results: The experimental group showed significant improvement in clinical reasoning competence (z=-2.29, p=.022), handoff performance (z=-2.23, p=.026), and self-efficacy of handoff (t=3.47, p=.001) compared to the control group.Conclusion: The results indicate that HECPAR is effective in improving clinical reasoning competence, self-efficacy for handoff, and handoff performance by new nurses. In addition, integrating concept mapping, PASS-BAR, and mentoring proved beneficial for handoff education for new nurses.
18
Mitsou, Evdokia K., Aimilia Kakali, Smaragdi Antonopoulou, Konstantinos C. Mountzouris, Mary Yannakoulia, Demosthenes B. Panagiotakos, and Adamantini Kyriacou. "Adherence to the Mediterranean diet is associated with the gut microbiota pattern and gastrointestinal characteristics in an adult population." British Journal of Nutrition 117, no. 12 (June 28, 2017): 1645–55. http://dx.doi.org/10.1017/s0007114517001593.
Full textAbstract:
AbstractThis study aimed to explore the potential associations of adherence to the Mediterranean diet with gut microbiota characteristics and gastrointestinal symptomatology in an adult population. Other long-term dietary habits (e.g. consumption of snacks and junk food or stimulant intake) were also evaluated in terms of the gut microbiota profile. Participants (n 120) underwent anthropometric, dietary, physical activity and lifestyle evaluation. Adherence to the Mediterranean diet was assessed using a Mediterranean diet score, the MedDietScore, and subjects were classified into three tertiles according to individual adherence scoring. Gut microbiota composition was determined using quantitative PCR and plate-count techniques, and faecal SCFA were analysed using GC. Gastrointestinal symptoms were also evaluated. Participants with a high adherence to the Mediterranean diet had lower Escherichia coli counts (P=0·022), a higher bifidobacteria:E. coli ratio (P=0·025), increased levels and prevalence of Candida albicans (P=0·039 and P=0·050, respectively), greater molar ratio of acetate (P=0·009), higher defaecation frequency (P=0·028) and a more pronounced gastrointestinal symptomatology compared with those reporting low adherence. A lower molar ratio of valerate was also observed in the case of high adherence to the Mediterranean diet compared with the other two tertiles (Pfor trend=0·005). Positive correlations of MedDietScore with gastrointestinal symptoms, faecal moisture, total bacteria, bifidobacteria:E. coli ratio, relative share of Bacteroides, C. albicans and total SCFA, as well as negative associations with cultivable E. coli levels and valerate were indicated. Fast food consumption was characterised by suppressed representation of lactobacilli and butyrate-producing bacteria. In conclusion, our findings support a link between adherence to the Mediterranean diet and gut microbiota characteristics.
19
Tacad, Debra Kirsty, Christine Bowlus, Leslie Woodhouse, Sridevi Krishnan, and Nancy Keim. "Linking Differences in Eating Behavior with Appetitive Hormones in Women." Current Developments in Nutrition 4, Supplement_2 (May 29, 2020): 594. http://dx.doi.org/10.1093/cdn/nzaa047_014.
Full textAbstract:
Abstract Objectives Examine and compare the hormones related to satiety in women identified as 1) restrained + disinhibited eaters, 2) restrained, non-disinhibited eaters, or 3) unrestrained, non-disinhibited eaters. We hypothesized restrained eaters with disinhibition would have a different pattern of appetitive hormones involved in food intake regulation. Methods 178 women from a cross-sectional study completed the three factor eating questionnaire (TFEQ), and were classified as restrained + disinhibited eaters (RD, n = 38), restrained, non-disinhibited eaters (R, n = 52), or unrestrained, non-disinhibited eaters (LL, n = 88). Women fasted for 12 h prior to baseline blood collection, and postprandial blood was collected after a meal challenge at 30 min, 3 h, and 6 h. Data were evaluated for outliers and missingness, and transformed and imputed using multivariate normal imputation. Differences in glucose, insulin and ghrelin were analyzed using a linear mixed model comparing groups. Time to peak and nadir for glucose, insulin and ghrelin were calculated from response curves. Chi square tests of proportions were used to determine whether the distribution of participants in the three groups were different in their times to peak and nadir. Results There were no significant differences between groups in ghrelin or insulin concentrations over time. However, overall glucose levels in RD were significantly lower than R and LL groups (P = 0.05 and P = 0.03, respectively). Chi-squared tests indicated that a greater proportion of women in the RD group reached peak glucose at 3 h, compared to women in R and LL with peak glucose occurring at 30 min (P = 0.04). Glucose nadir displayed a bimodal distribution in R, with more women at baseline and 3 h compared to RD and LL (P = 0.05). Ghrelin nadir was reached at 3 h for more participants in RD and LL, but occurred later at 6 h in more participants in R (P = 0.04). Conclusions Dietary restraint and disinhibition are associated with circulating glucose and ghrelin concentrations; however, prospective research is needed to determine if there is a causal relationship. Funding Sources USDA CRIS 2032-51530-022, 2032-51530-025, and 2032-51530-026-00-D, and a grant from Arla Foods Inc.
20
Stover, Sheri, Sharon Heilmann, and Amelia Hubbard. "Learner-Centered Design." Journal of Effective Teaching in Higher Education 1, no. 1 (November 3, 2018): 1–19. http://dx.doi.org/10.36021/jethe.v1i1.16.
Full textAbstract:
This quantitative research study examined one instructor’s redesign of her introductory Anthropology course (N = 265) from Teacher-Centered (TC) to Learning-Centered (LC) and the resulting impact on her students’ perceptions of Teaching Presence (TP), Social Presence-Interaction (SP-I), Social Presence- Participation (SP-P), Cognitive Presence (CP), and Satisfaction (SAT). Using the Community of Inquiry (CoI) survey (Swan, Richardson, Ice, Garrison, Cleveland-Innes, & Arbaugh, 2008) in a face-to-face classroom environment; results indicated that implementing a LC classroom compared to a TC classroom was found to have a significantly positive impact on students’ perceptions of TP (p = .021), SP-I (p < .001), SP-P (p < .001), CP (p = 002), and SAT (p = .022). Multiple regression results indicated that TP, SP-I-, and SP-P were able to predict 42% of students’ level of satisfaction score with TP having the highest level of prediction (β=.37). Preliminary evidence suggests that instructors who implement LC teaching methodologies can have a positive impact on TP, SP-I, SP-P, CP, and SAT.
21
Togari, K., and M. Akasaka. "Okhotskite, a new mineral, an Mn3+-dominant member of the pumpellyite group, from the Kokuriki mine, Hokkaido, Japan." Mineralogical Magazine 51, no. 362 (October 1987): 611–14. http://dx.doi.org/10.1180/minmag.1987.051.362.17.
Full textAbstract:
AbstractOkhotskite, an Mn3+-dominant pumpellyite-group mineral, is monoclinic, A2/m, a = 8.887, b = 6.000, c = 19.55 Å, β = 97.08°, Z = 1. The formula is(Ca7.63Na0.17K0.01)Σ7.81(Mn2.752+Mg1.10)Σ3.85(Mn4.503+Al1.87Fe1.613+Ti0.02)Σ8.00Si12.13O39.71(OH)16.29,which simplifies to Ca8(Mn2+,Mg)4(Mn3+,Al,Fe3+)8Si12O5∂-n(OH)n. Strong lines in the X-ray powder diffraction pattern are: 4.76(60)(004, 111), 3.87(70)(202), 2.96(100)(115, 300), 2.88(25)(022), 2.72(70)(302), 2.67(45)(3̄04, 3̄11), 2.55(45)(024, 3̄13) and 2.38(45)(304).Its colour is deep orange with a pale orange streak and vitreous lustre. Transparent. Non-fluorescent. H6 (Mohs). Density (calc.) = 3.40 g/cm3. Optically biaxial negative, 2V(meas) = 46(5)°, 2V(calc) = 46°, dispersion indiscernible. Refractive indices: α = 1.782(5), β = 1.820(5), γ = 1.827(5). Orientation: Y = b, c∧Z = 9–14° in acute angle of β. Pleochroism is distinct: X yellow, Y and Z deep orange. Absorption: X < Y < Z.This mineral occurs as fine prisms up to 0.2 mm long and forms aggregates in network veinlets cutting hematite ore from the Kokuriki mine in the Tokoro district, eastern Hokkaido, Japan. Associated minerals are: hematite, piemontite, quartz, neotocite, bementite, apatite, Mn-oxides, inesite and rhodochrosite. The mineral is named okhotskite for the Sea of Okhotsk, along which the mine is located.
22
Venugopal, Adith, Harsh Tejani, Paolo Manzano, and Ronaldo G. Vergara. "Comparison of Two Different Orthodontic Bracket Recycling Techniques." Orthodontic Journal of Nepal 6, no. 2 (December 31, 2016): 28–32. http://dx.doi.org/10.3126/ojn.v6i2.17417.
Full textAbstract:
Introduction: The cost of orthodontic treatment in most of the industrialized countries may considerably differ from those in third world countries. The lesser cost of orthodontic treatment, high pricing of orthodontic inventory and poor economic conditions of the people strengthen the notion of ‘recycling’ even more.Objectives: To compare the shear bond strengths of .022 slot pre-adjusted edgewise brackets with conventional mesh base design recycled by two different chair-side techniques, one being flaming/heating and other being sandblasting.Materials & Method: The sample involved eighty extracted human premolars with .022 slot pre-adjusted edgewise brackets (Orcmo, USA) bonded onto the lingual surface. After initial de-bonding the bracket base was studied under a scanning electron microscope at different magnifications for aperture size, mesh continuity and surface roughness. The brackets were re-bonded on to the labial surface of the same premolars and then debonded using a Universal Testing Machine to produce a shear force at the tooth bracket interface.Result: The study showed highest bond strengths with the control group (111.52 ± 49.90 N) and least bond strengths with the heating/flaming group (63.71 ± 22.43 N). Reduced aperture dimensions and loss of mesh continuity were characteristics of the Heating group. Sand Blasting showed significantly higher bond strengths (100.42 ± 39.42 N) with considerably rougher mesh surface texture compared to heating group.Conclusion: Sand blasting as a mode to reconditioned orthodontic bracket base provides a higher shear bond strength compared to orthodontic brackets reconditioned by heating/ flaming (p< .01).
23
Kim, Do Hyun, Yeonji Kim, Il Gye Lim, Jin Hee Cho, Yong Jin Park, Sung Won Kim, and Soo Whan Kim. "Effect of Postoperative Xylitol Nasal Irrigation on Patients with Sinonasal Diseases." Otolaryngology–Head and Neck Surgery 160, no. 3 (October 2, 2018): 550–55. http://dx.doi.org/10.1177/0194599818802815.
Full textAbstract:
Objective To examine the effect of xylitol nasal irrigation in a large sample size of patients who had undergone nasal surgery. Study Design Double-blinded randomized controlled crossover study. Setting Tertiary referral center. Methods The study included 100 patients with sinonasal disease who underwent endoscopic sinus surgery (ESS), septoplasty, or both concurrently. To identify patients with allergic sensitization, serum-specific immunoglobulin E levels were measured. Nasal symptoms were evaluated with the NOSE (Nasal Obstruction Symptoms Evaluation) and SNOT-20 (Sino-Nasal Outcome Test–20) and via visual analog scale (VAS) scores. Results In the ESS group (n = 34), the general nasal symptom score evaluated by the SNOT-20 showed significantly greater improvement in the xylitol group versus the saline group ( P = .022). VAS symptom scores for sneezing ( P = .003), headache ( P = .02), and facial pain ( P = .037) were also more improved in the xylitol group. In the septoplasty group (n = 39), the VAS score for nasal stuffiness showed a significantly greater improvement in the xylitol group when compared with the saline irrigation group ( P = .001). Among the patients with allergic sensitization (n = 31), rhinorrhea symptoms improved significantly more in the xylitol group than in the saline group ( P = .024). The preference survey showed that more than half of the patients in each surgical group preferred xylitol irrigation. Conclusion We found that xylitol nasal irrigation was useful in postoperative ESS and septoplasty care. For patients with allergic sensitization, rhinorrhea showed greater improvement in the xylitol group than in the saline group.
24
Isart, Fernando A., Faustino G. Ramos, and Fernando Isart-Infante. "Cardiac Early Repolarization Pattern Anomalies Among Children and Adolescents With and Without Attention-Deficit Hyperactivity Disorder: A Community Observational Study." Global Pediatric Health 6 (January 2019): 2333794X1982831. http://dx.doi.org/10.1177/2333794x19828311.
Full textAbstract:
Our research had 2 aims, first, to determine if electrocardiographic early repolarization pattern anomalies (ERPAs) were more likely present among children and adolescents diagnosed with attention-deficit hyperactivity disorder (ADHD; n = 416) when compared with non-ADHD children (n = 187), and second, to asses if ADHD patients whose parents report severe ADHD psychometric scores were more likely to have ERPA in their surface ECG (electrocardiography) when compared with other ADHD patients with mild to moderate dysfunction or no dysfunction. In our unmatched case-control study, ERPA was recognized when there was an end QRS notch (J wave) or slur on the downslope of a prominent R wave with and without ST-segment elevation and the peak of the notch or J wave (Jp) ≥0.1 mV in ≥2 contiguous leads, excluding V1-V3 anterior lead, and QRS duration (measured in leads in which a notch or slur is absent) <120 ms or ST-segment elevation >0.1 mV in ≥2 contiguous leads, excluding V1-V3, and QRS duration <120 ms. The DSM-IV ( Diagnostic and Statistical Manual of Mental Disorders, 4th edition) criteria were used to diagnose ADHD. Our data analysis suggested a significant association between ERPA presence and ADHD (n = 603, P = .020). Our logistic regression model suggests that patients with ERPA (n = 167) were 2.778 times more likely to have a diagnosis of ADHD after controlling for age, gender, and ethnicity (95% confidence interval for odds ratio 1.087-7.100, P = .033). Multiple regression models suggested that age, P < .001; gender, P < .001; ERPA, P = .004; and ERPA leads number, P = .022, were significant predictors of global parental ADHD worry scale. Hispanic and black ethnicity were not significant predictors. Consequently, the presence of ERPA should be reported in all ECGs done in children and adolescents for prospective behavioral phenotype and/or arrhythmia risk stratification analysis.
25
Lee, Kwang-Jin. "Effect of Circuit Type Neuromuscular Training on Strength, Power, and Functional Performance in MZ Generation." Exercise Science 31, no. 2 (May 31, 2022): 215–21. http://dx.doi.org/10.15857/ksep.2022.00101.
Full textAbstract:
PURPOSE: This study aimed to investigate the effects of circuit-type neuromuscular training (CTNT) on strength, power, and functional performance among the MZ generation.METHODS: Twenty-eight participants were assigned to either the circuit-type neuromuscular training group (CTNTG, n=14) or the control group (CG, n=14). CTNT was performed for 50 minutes a day, 2–3 times a week, for 6 weeks. The CG only performed activities of daily living during the study period. Baseline and post measures included isometric muscular strength (knee flexion, knee extension, back flexion, back extension), vertical jump, 30 m sprint, T-agility, and Y-balance tests.RESULTS: The results showed that the CTNT had a positive effect on the improvement of knee flexion (<i>p</i>=.015), knee extension (<i>p</i>=.047), back extension (<i>p</i>=.003), vertical jump (<i>p</i>=.025), T-agility (<i>p</i>=.046), posteromedial (<i>p</i>=.031), posterolateral (<i>p</i>=.022), and composite score (<i>p</i>=.032).CONCLUSIONS: These findings can be a factor that the strength, power, and functional performance of MZ generation can be sufficiently improved through the CTNT program. This suggests that CTNT is the most appropriate exercise intervention method to improve the strength, power, and functional performance of the MZ generation.
26
Wu, Cong, Xiaoyun Chen, Yideng Huang, Min Zhang, Fan Ye, and Xianmin Wu. "Comparison of Tympanic Membrane Perforation With and Without Calcification of Anterior Mallear Ligament Under Transcanal Endoscopic Type I Tympanoplasty." Ear, Nose & Throat Journal 100, no. 6 (May 16, 2021): 411–16. http://dx.doi.org/10.1177/01455613211010092.
Full textAbstract:
Objectives: Chronic suppurative otitis media (CSOM) induced tympanic membrane perforation (TMP) can be accompanied by anterior mallear ligament (AML) calcification. So far, comparative evaluations of TMP with and without AML calcification have rarely been reported. The aim of the current study is to compare the hearing outcomes of TMP with and without calcification of AML under transcanal endoscopic type I tympanoplasty. Methods: Records of 67 patients diagnosed with CSOM and receiving transcanal endoscopic type I tympanoplasty were divided into the AML calcification group (Cal group, n = 31) and the non-AML calcification group (non-Cal group, n = 36). The 31 patients in the Cal group were divided into subgroup A and B according to the severity of calcification. The operation time, closure rate, and pre- and postoperative audiometric results were retrospectively collected and analyzed. Results: Preoperatively, the Cal group had higher mean air–bone gap (ABG; P = .022), and ABGs at 250 Hz ( P = .017) and 500 Hz ( P = .008) compared with the non-Cal groups. The Cal group showed higher improvements of ABGs at 250 Hz ( P = .039) and 500 Hz ( P = .021) compared with the non-Cal groups postoperatively. Conclusions: The TMP with AML calcification leads to higher ABGs at low frequencies. The hearing outcomes are similar for TMP both with and without AML calcification after surgery. Our results suggest that transcanal endoscopic type I tympanoplasty is an appropriate surgical method for TMP with AML calcification, if the lesion can be detected and completely eliminated.
27
Berenson, James, Richard Cook, Allan Lipton, Robert Coleman, and Evangelos Terpos. "Increased Levels of Urinary N-Telopeptide of Type I Collagen Correlate with Reduced Survival in Patients with Advanced Multiple Myeloma." Blood 110, no. 11 (November 16, 2007): 1499. http://dx.doi.org/10.1182/blood.v110.11.1499.1499.
Full textAbstract:
Abstract Staging systems such as those of Durie-Salmon and the International Staging System provide important prognostic insight for patients (pts) with multiple myeloma (MM) throughout the disease continuum. However, detailed evaluations of prognostic factors in pts with advanced MM and primary bone lesions have not been reported. Therefore, an exploratory analysis of data was conducted from a randomized trial in pts with bone disease from MM to assess prognostic factors for survival (n=282). Patients received standard antineoplastic therapy including a bisphosphonate (zoledronic acid 4 mg, n=184; pamidronate 90 mg, n=98) every 3 to 4 weeks for up to 24 months. Dichotomous variables included sex, race (white/other), narcotic analgesics (yes/no), Eastern Cooperative Oncology Group performance status (active/impaired), prior skeletal-related event (SRE; yes/no), and values with a defined upper limit of normal (creatinine, lymphocyte %, hemoglobin, serum glutamic-oxaloacetic transaminase, albumin, lactate dehydrogenase [LDH], and calcium). Continuous variables included age, weight, cancer duration, Functional Assessment of Cancer Therapy-General score, Brief Pain Inventory score, and bone markers (eg, urinary N-telopeptide of type I collagen [NTX], deoxypyridinoline). Paraprotein type was also included. Univariate and multivariate analyses were developed to determine relative risks (RR) for reduced survival associated with baseline variables using Cox regression models, and those that were not significant at the 5% level were removed by backward elimination to generate a reduced model. In the reduced multivariate model, advanced age (P=.001), non-immunoglobulin (Ig) G myeloma subtype (IgA [P=.001] or light chain/nonsecretory/IgM [P=.051]), history of SREs before study enrollment (P=.004), anemia (P=.022), high urinary levels of NTX (P=.017), high serum levels of LDH (P=.014), and low serum levels of albumin (P=.025) significantly correlated with reduced survival. Because NTX levels were a significant covariate, the correlation between baseline NTX and survival was assessed. Normal NTX (< 50 nmol/mmol creatinine) was associated with a significant 47% lower risk of death versus elevated NTX in pts who received zoledronic acid (n=210; RR=0.53; P=.026); it was associated with a 38% lower risk in the smaller population of pts who received pamidronate (n=108; RR=0.62; P=.135). After 3 months of bisphosphonate treatment, a 50% reduction in NTX was achieved in approximately 83% of patients with an elevated baseline NTX (median, 82.5 nmol/mmol creatinine) who were treated with zoledronic acid. However, the same NTX reduction at 3 months was achieved in only 67% of pts with an elevated baseline NTX (median, 80.0 nmol/mmol creatinine) who were treated with pamidronate. In these analyses, age, albumin, Igs, and anemia were identified as prognostic factors for reduced survival in pts with advanced MM. In addition, a history of SREs before study enrollment and elevated levels of bone metabolism markers—specifically NTX—were identified. Bisphosphonates can delay the onset of potentially life-limiting skeletal complications and reduce NTX levels. Therefore, studies are under way to investigate whether bisphosphonates can improve survival in this setting.
28
Fisher, Alana, Christina Marel, Maree Teesson, and Katherine Mills. "Assessing patient information and decision-support needs in problematic alcohol use and co-occurring depression to inform shared decision-making interventions." Bulletin of the Menninger Clinic 85, no. 2 (June 2021): 143–76. http://dx.doi.org/10.1521/bumc.2021.85.2.143.
Full textAbstract:
The authors assessed the informational and decision-support needs of patients, families, and clinicians when deciding on treatment for problematic alcohol use and depression. Patients (n = 56), family members (n = 16), and clinicians (n = 65) with experience deciding on treatment for problematic alcohol use and depression were eligible. Participants completed an online decisional needs assessment survey. Stakeholder groups identified numerous difficult patient-level treatment decisions and elevated decisional conflict. Participants preferred patient-led or shared treatment decision-making (75%-95.4%). Patients (32.6%) reported not being as involved in treatment decision-making as preferred, a higher proportion than reported by clinicians (16.4%; p = .056). More patients (19.6%) than clinicians (3.6%) reported clinician-led treatment decision-making, with little or no patient involvement (p = .022). Stakeholder preferences for future decision-support resources included online information for use outside consultations.
29
Machado, Roberto F., Robyn J. Barst, Nancy A. Yovetich, Kathryn L. Hassell, Gregory J. Kato, Victor R. Gordeuk, J. Simon R. Gibbs, et al. "Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity." Blood 118, no. 4 (July 28, 2011): 855–64. http://dx.doi.org/10.1182/blood-2010-09-306167.
Full textAbstract:
Abstract In adults with sickle cell disease (SCD), an increased tricuspid regurgitation velocity (TRV) by Doppler echocardiography is associated with increased morbidity and mortality. Although sildenafil has been shown to improve exercise capacity in patients with pulmonary arterial hypertension, it has not been evaluated in SCD. We therefore sought to determine whether sildenafil could improve exercise capacity in SCD patients with increased TRV and a low exercise capacity. A TRV ≥ 2.7 m/s and a 6-minute walk distance (6MWD) between 150 and 500 m were required for enrollment in this 16-week, double-blind, placebo-controlled sildenafil trial. After 74 of the screened subjects were randomized, the study was stopped early due to a higher percentage of subjects experiencing serious adverse events in the sildenafil arm (45% of sildenafil, 22% of placebo, P = .022). Subject hospitalization for pain was the predominant cause for this difference: 35% with sildenafil compared with 14% with placebo (P = .029). There was no evidence of a treatment effect on 6MWD (placebo-corrected effect −9 m; 95% confidence interval [95% CI] −56-38; P = .703), TRV (P = .503), or N-terminal pro-brain natriuretic peptide (P = .410). Sildenafil appeared to increase hospitalization rates for pain in patients with SCD. This study is registered at www.clinicaltrials.gov as NCT00492531.
30
Dagger, Rebecca M., Ian G. Davies, Kelly A. Mackintosh, Genevieve L. Stone, Keith P. George, Stuart J. Fairclough, and Lynne M. Boddy. "The CHANGE! Project: Changes in Body Composition and Cardiorespiratory Fitness in 10- to 11-Year-Old Children After Completing the CHANGE! Intervention." Pediatric Exercise Science 30, no. 1 (February 1, 2018): 81–89. http://dx.doi.org/10.1123/pes.2015-0200.
Full textAbstract:
Purpose: To assess the effects of the Children’s Health, Activity and Nutrition: Get Educated! intervention on body size, body composition, and peak oxygen uptake in a subsample of 10- to 11-year-old children. Methods: Sixty children were recruited from 12 schools (N = 6 intervention) to take part in the CHANGE! subsample study. Baseline, postintervention, and follow-up measures were completed in October 2010, March–April 2011, and June–July 2011, respectively. Outcome measures were body mass index z score, waist circumference, body composition assessed using dual-energy X-ray absorptiometry (baseline and follow-up only), and peak oxygen uptake. Results: Significant differences in mean trunk fat mass (control = 4.72 kg, intervention = 3.11 kg, P = .041) and trunk fat % (control = 23.08%, intervention = 17.75%, P = .022) between groups were observed at follow-up. Significant differences in waist circumference change scores from baseline to follow-up were observed between groups (control = 1.3 cm, intervention = −0.2 cm, P = .023). Favorable changes in body composition were observed in the intervention group; however, none of these changes reached statistical significance. No significant differences in peak oxygen uptake were observed. Conclusions: The results of the present study suggest the multicomponent curriculum intervention had small to medium beneficial effects on body size and composition health outcomes.
31
Charlet, K., A. Beck, A. Jorde, S. Vollstädt-Klein, J. Gallinat, H. Walter, F. Kiefer, and A. Heinz. "P.1.i.022 Neural activity during the “n-back” working memory task predicts relapse risk in alcohol dependence." European Neuropsychopharmacology 24 (October 2014): S309—S310. http://dx.doi.org/10.1016/s0924-977x(14)70491-2.
Full text
32
Leal, Diogo V., Lee Taylor, and John Hough. "Exercise-Induced Salivary Hormone Responses to High-Intensity, Self-Paced Running." International Journal of Sports Physiology and Performance 16, no. 9 (September 1, 2021): 1319–27. http://dx.doi.org/10.1123/ijspp.2020-0541.
Full textAbstract:
Purpose: Physical overexertion can lead to detrimental overreaching states without sufficient recovery, which may be identifiable by blunted exercise-induced cortisol and testosterone responses. A running test (RPETP) elicits reproducible plasma cortisol and testosterone elevations (in a healthy state) and may detect blunted hormonal responses in overreached athletes. This current study determined the salivary cortisol and testosterone responses reproducibility to the RPETP, to provide greater practical validity using saliva compared with the previously utilized blood sampling. Second, the relationship between the salivary and plasma responses was assessed. Methods: A total of 23 active, healthy males completed the RPETP on 3 occasions. Saliva (N = 23) and plasma (N = 13) were collected preexercise, postexercise, and 30 minutes postexercise. Results: Salivary cortisol did not elevate in any RPETP trial, and reduced concentrations occurred 30 minutes postexercise (P = .029, η2 = .287); trial differences were observed (P < .001, η2 = .463). The RPETP elevated (P < .001, η2 = .593) salivary testosterone with no effect of trial (P = .789, η2 = .022). Intraindividual variability was 25% in cortisol and 17% in testosterone. “Fair” intraclass coefficients of .46 (cortisol) and .40 (testosterone) were found. Salivary and plasma cortisol positively correlated (R = .581, P = .037) yet did not for testosterone (R = .345, P = .248). Conclusions: The reproducibility of salivary testosterone response to the RPETP is evident and supports its use as a potential tool, subject to further confirmatory work, to detect hormonal dysfunction during overreaching. Salivary cortisol responds inconsistently in a somewhat individualized manner to the RPETP.
33
Alghadeer, Sultan, Reham M. Binhazza, Abdulrahman Alwahibi, Feda F. Alsaloom, Abdulrahman I. Alshaya, Hayaa Alyahya, Abrar Al-Ghamdi, and Abdulrahman A. Alghamdi. "Use of antiepileptic medications for seizures’ prevention during subarachnoid hemorrhage: A retrospective observational study." Medicine 103, no. 28 (July 12, 2024): e38959. http://dx.doi.org/10.1097/md.0000000000038959.
Full textAbstract:
The use of prophylactic antiepileptic drugs (AEDs) post-subarachnoid hemorrhage (SAH), particularly aneurysmal SAH, is controversial, with limited data available. This has led the new American Heart Association/American Stroke Association (AHA/ASA) guidelines to recommend against using AEDs. This study is aimed at determining whether the use of AEDs for primary prophylaxis is effective in reducing the incidence of seizures post-SAH. A retrospective observational study was conducted utilizing a reviewing chart for the period starting from June 2015 to the end of 2021. The reviews were conducted in the acute care areas of 2 tertiary hospitals primarily to assess the efficacy of AEDs against seizures in patients with SAH (particularly aneurysmal SAH). This was done by comparing the occurrence of early, late, and overall incidence of seizures between patients who received AEDs versus those who did not. Of the 62 patients, who mostly presented with aneurysmal SAH (71%), 42 received AEDs and 20 did not. Mostly, the baseline characteristics between the 2 groups were comparable. A few patients on AEDs developed early (n = 4/38), late (n = 3/29), and overall seizures (n = 6/33), whereas no early, late, or overall incidence of seizures was presented in the group who did not receive AEDs. However, this difference showed no significance (P > .05). The subjects who were given AEDs showed significantly longer hospital stays (42.11 ± 51.43 vs 14.10 ± 7.17; P = .002) and higher mortality rates (7/11 vs 0/11; P = .026). For all patients who received AEDs for prophylaxis, the overall incidence of seizures was negatively associated with the Glasgow coma scale (OR: 0.798; 95% CI 0.657–0.978; P = .022). Our findings support the 2023 AHA/ASA guideline recommendation to avoid using routine AEDs for prophylaxis for all SAH patients. Proper and careful stratification methods should be implemented in each given scenario.
34
Mehta-Shah, Neha, Kimiteru Ito, Kurt Bantilan, Alison J. Moskowitz, Craig Sauter, Steven M. Horwitz, and Heiko Schöder. "Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma." Blood Advances 3, no. 2 (January 22, 2019): 187–97. http://dx.doi.org/10.1182/bloodadvances.2018024075.
Full textAbstract:
Abstract The prognosis of peripheral T-cell lymphoma (PTCL) is heterogenous. Baseline or interim imaging characteristics may inform risk-adapted treatment paradigms. We identified 112 patients with PTCL who were consecutively treated with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)/CHOP-like regimens with the intent to consolidate with an autologous transplant. Baseline (n = 93) and interim (after 4 cycles, n = 99) positron emission tomography (PET) images were reevaluated, and we calculated baseline total metabolic tumor volume (TMTV). Interim PET (iPET) responses were graded visually by 5-point score (i5PS) and by percentage change of standardized uptake value. By univariate analysis, predictors of event-free survival (EFS) included Prognostic Index for Peripheral TCL (PIT) higher than 1 (hazard ratio [HR], 1.83; P = .021), International Prognostic Index (IPI) higher than 3 (HR, 2.01; P = .021), high TMTV (>125 cm3; HR, 3.92; P = .003), and positive iPET (HR, 3.57; P < .001). By multivariate analysis, high baseline TMTV predicted worse overall survival (OS; HR, 6.025; P = .022) and EFS (HR, 3.861; P = .005). Patients with i5PS of 1 to 3 had a longer median OS and EFS (104 months, 64 months) than those with i5PS of 4 to 5 (19 months, 11 months; P < .001). Four-year OS and EFS for patients with i5PS of 1 to 3 and PIT of 1 or less were 85% and 62%, respectively. However, 4-year OS and EFS for those with i5PS of 4 to 5 and PIT higher than 1 were both 0% (P < .001). In multivariate analysis, after controlling for IPI and PIT, i5PS was independently prognostic for EFS (HR, 3.400 95% confidence interval, 1.750-6.750; P < .001) and OS (HR, 10.243; 95% confidence interval, 4.052-25.891; P < .001). In conjunction with clinical parameters, iPET helps risk stratify patients with PTCL and could inform risk-adapted treatment strategies. Prospective studies are needed to confirm these findings.
35
Babiker, Amir, Nawaf Alammari, Abdulrahman Aljuraisi, Rakan Alharbi, Hamoud Alqarni, Emad Masuadi, and Haifa Alfaraidi. "The Effectiveness of Insulin Pump Therapy Versus Multiple Daily Injections in Children With Type 1 Diabetes Mellitus in a Specialized Center in Riyadh." Clinical Medicine Insights: Endocrinology and Diabetes 15 (January 2022): 117955142211284. http://dx.doi.org/10.1177/11795514221128495.
Full textAbstract:
Objectives: Comparison of continuous subcutaneous insulin infusion (CSII) with multiple daily injections (MDI) in achieving glycemic control in youths with type 1 diabetes mellitus (T1DM). Methods: Retrospective cohort study including 2 matched groups of youths with T1DM treated by CSII or MDI in a tertiary specialized children’s hospital in Saudi Arabia. Children and adolescents aged up to 18 years, diagnosed with T1DM and using CSII or MDI, from the period 2016 to 2018. Patients on MDI were newly-diagnosed patients with T1DM who had the disease for only 1 year duration; all CSII patients had at least 1 to 2 years of T1DM but who had just started on pumps in the past 3 months. We excluded patients with other autoimmune diseases, non-ambulatory patients and those admitted to hospital for non-diabetes reasons. Primary outcome was HbA1c at 1, 2, and 3 years, with weight gain as a secondary outcome. Ambulatory glycemic profile was analyzed from a subset of patients using intermittently scanned continuous glucose monitoring (isCGM). Results: A total of 168 youths with T1DM (n = 129 in the MDI group, n = 39 in the CSII group) were included. The CSII group consistently had lower HbA1c levels compared to the MDI group throughout a 3-year follow up period: 8.1% versus 10.1, P-value < .001 at 1 year, 7.5% versus 10.1% at 2 years, P-value < .001, 8.9% versus 10.3% at 3 years, P-value = .033. Body mass index significantly increased in both groups at 1 year, although greater in CSII group. In a subgroup using isCGM (n = 37 on MDI and n = 29 on CSII), the CSII group had a lower average blood glucose (194 mg/dL vs 228 mg/dL, P-value = .028) and a lower estimated HbA1c level (8.4% vs 9.6%, P-value = .022). Conclusion: Treatment with CSII resulted in lower HbA1c compared to MDI in our cohort, which was sustained over a 3-year period.
36
Hartupee, Conner D., Denise Danos, Eileen T. Mederos, Augusto Ochoa, Valentine N. Nfonsam, and Omeed Moaven. "Healthcare disparities are associated with eligibility and enrollment in clinical trials in Louisiana." Journal of Clinical Oncology 42, no. 16_suppl (June 1, 2024): e13728-e13728. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e13728.
Full textAbstract:
e13728 Background: Clinical trials offer an opportunity to evaluate novel therapeutic strategies and modalities of care. Overall enrollment is low for clinical trials, but previous literature has highlighted lower rates of enrollment among underrepresented populations. A disproportionately low accrual of minority or other populations will result in reducing the ability of such clinical trials to prove general benefit to the overall population. This study aims to evaluate the population of those able or unable to qualify for and enroll in the Gulf South Clinical Trials network, a minority/underserved NCORP community site. Methods: Patient data was collected through interviews using a screening tool developed by the National Cancer Institute’s Community Oncology and Prevention Trials Research Group and active enrollment of ongoing clinical trials. Patients were interviewed regarding demographic data and tumor staging. Reason for ineligibility or non-enrollment was documented by the clinical staff. Clinical trials were categorized between Cancer-Control and Cancer Care Delivery Research (CC-CCDR) Trials and Cancer Treatment Trials from 2017 and 2023. Rates of eligibility and enrollment were compared via Fisher’s Exact tests. Results: CC-CCDR Trials had 363 participants while Cancer Treatment had 550 participants. CC-CCDR Trials resulted in 19% (n=69) of patients being ineligible with 81% (n=294) being eligible with a higher proportion of Whites (p<.001), non-rural (p = .021), low income (p=.007), private insurance (p=<.001), stage 1 tumors (p<.001), and having a genetic predisposition (p<.001) being ineligible. From the patients that were eligible, 13% (n= 39) of patients were not enrolled with 87% (n=255) of patients enrolled. Cancer Treatment Trials resulted in 23% (n=129) of ineligible patients and 76.5% (n=421) of eligible patients, with a higher proportion of low income (p=.002), private insurance (p=.035), and those not having genetic predispositions (p=.022) being ineligible. From the participants that were eligible, 20% (n=85) of patients were not enrolled with 80% (n=336) of patients enrolled, with a higher proportion of female (p= .002) patients not enrolled. Conclusions: Disparities in socioeconomic factors and female gender are associated with lower rates of eligibility and enrollment in clinical trials in community oncology settings. Future research identifying modifiable underlying factors can assist in developing strategies to improve enrollment in underserved populations.
37
Pillay, Julian David, Tracy L. Kolbe-Alexander, Karin I. Proper, Simone A. Tomaz, Willem Van Mechelen, and Estelle V. Lambert. "Steps that count: Pedometer-measured physical activity, self-reported physical activity and current physical guidelines ‒ how do they relate?" South African Journal of Sports Medicine 26, no. 3 (September 29, 2014): 77. http://dx.doi.org/10.17159/2413-3108/2014/v26i3a102.
Full textAbstract:
Background. The association between self-perceived and actual physical activity, with particular reference to physical activity guidelines, may be an important factor in determining the extent of uptake of and compliance with physical activity.Objectives. To examine the association between self-perceived and actual physical activity in relation to physical activity guidelines, with reference to volume, intensity and duration of steps/day, and to establish the level of agreement between pedometer-measured and selfreported ambulatory physical activity, in relation to current guidelines.Methods. A convenience sample of adults (N=312; mean (standard deviation) age 37 (9) years), wore a pedometer (minimum 3 consecutive days) and completed a questionnaire that included information on physical activity patterns. Analyses of covariance, adjusted for age and gender, compared volume- and intensity-based steps according to meeting/not meeting guidelines (self-reported). The extent of agreement between self-reported and pedometer-measured physical activity was also determined.Results. Average (SD) steps/day were 6 574 (3 541). Of a total of 312 participants’ self-reported data, those meeting guidelines (n=63) accumulated significantly more steps/day than those not meeting guidelines (8 753 (4 251) v. 6 022 (3 114) total steps/day and 1 772 (2 020) v. 421 (1 140) aerobic steps/day, respectively; p<0.0001). More than half of the group who self-reported meeting the guidelines did not meet guidelines as per pedometer data.Conclusion. The use of pedometers as an alternative and/or adjunct to self-reported measures is an area for consideration. Steps/day recommendations that consider intensity-based steps may provide significant effects in improving fitness and health.
38
Patenaude, Alexandre, Jessica S. Fortin, Réna Deschenes, Marie-France Côté, Jacques Lacroix, René C.-Gaudreault, and Éric Petitclerc. "Chloroethyl urea derivatives block tumour growth and thioredoxin-1 nuclear translocation." Canadian Journal of Physiology and Pharmacology 88, no. 11 (November 2010): 1102–14. http://dx.doi.org/10.1139/y10-084.
Full textAbstract:
Aryl chloroethyl ureas (CEUs) are new protein alkylating agents exhibiting anticancer activity both in vitro and in vivo. We report herein that 14C-labeled CEU derivatives, designated CEU-025 and CEU-027, covalently bind to thioredoxin-1 (TRX1). Covalent binding of these molecules slightly decreases the disulfide-reducing activity of recombinant TRX1, when compared with the effect of strong thioalkylating agents such as N-ethylmaleimide. Moreover, site-directed mutagenesis and diamide competition assays demonstrated that TRX1 cysteinyl residues are not the prime targets of CEUs. CEU-025 abrogates the nuclear translocation of TRX1 in human cancer cells. In addition, we show that CEU-025 can block TRX1 nuclear translocation induced by cisplatin. Unexpectedly, pretreatment with sublethal CEU-025 concentrations that block TRX1 nuclear translocation protected the cells against cisplatin cytotoxicity. Overexpression of TRX1 in HT1080 fibrosarcoma cells attenuated CEU-025 cytotoxicity, while its suppression using TRX1-specific siRNA increased the effects of CEU-025, suggesting that loss of function of TRX1 is involved, at least in part, in the cytotoxic activity of CEU-025. These results suggest that CEU-025 and CEU-027 exhibit anticancer activity through a novel, unique mechanism of action. The importance of TRX1 and the dependence of the cytotoxicity of CEU-025 and CEU-027 on TRX1 intracellular localization are also discussed.
39
اذبيب, إحسان جالي. "Effect of salinity with use Different concentration 0f NaCI on some of growth properties and yield of Broad bean (Vicia faba L .) plant." University of Thi-Qar Journal of Science 3, no. 4 (September 9, 2013): 49–56. http://dx.doi.org/10.32792/utq/utjsci/v3i4.546.
Full textAbstract:
أجريت الد ا رسة الحالية في احد الحقول الأهلية في ناحية الغ ا رف / محافظة ذي قا ر بهدف معرفة تأثير الإجهاد الملحي باستخدام ت ا ركيزفي بعض صفات النمو والحاصل لمحصول الباقلاء إذ تم ز ا رعة صنف الباقلاء الاسباني NaCl مختلفة من محلول كلوريد الصوديومخلال الموسم الخريفي 0202 . نفذت تجربة عاملية بتصميم القطاعات العشوائية الكاملة وبثلاثة مكر ا رت حيث شملت Reina mora022 ملي مول.لتر- 0 (. وقد ، 002 ، 022 ، 02 ، المعاملات خمسة ت ا ركيز من الإجهاد الملحي ممثلة بكلوريد الصوديوم وهي ) 2أظهرت النتائج إن جميع ت ا ركيز الإجهاد الملحي أدت إلى انخفاض معنوي في جميع صفات النمو والحاصل المدروسة قياسا بمعاملة السيطرة022 مول.لتر- 0 معنويا على باقي المعاملات وأعطت اقل معدل في صفات ) طول النبات وطول القرنة والحاصل C . إذ تفوقت معاملة 4002 مول.لتر- 0 إلى حدوث انخفاض معنوي في معدل صفات ) الوزن الجاف C الكلي ( بينما لم يؤدي زيادة التركيز الملحي عن معاملة 3لكل من المجموع الخضري والجذري وعدد العقد البكتيرية والقرنات ( و أعطت 28.5 و 15.5 و 32.8 و 8.09 غم / نبات على الوالي ،100 مول.لتر- 0 إلى انخفاض معنوي في صفة ) عدد الأفرع / نبات ( . كما بينت النتائج C كما لم تؤدي زيادة التركيز الملحي عن معاملة 2و P و الفسفور N إن جميع معاملات الإجهاد الملحي أدت إلى انخفاض معنوي في محتوى الأو ا رق من المغذيات متمثلة) النتروجينبلغت أقصاها عند أعلى )
40
Datta, Anita N., Laura Wallbank, Johann Micallef, and Peter K. H. Wong. "Pediatric Occipital Spikes at a Single Center Over 26 Years and the Significance of Tangential Dipole." Journal of Child Neurology 36, no. 7 (January 6, 2021): 530–36. http://dx.doi.org/10.1177/0883073820984042.
Full textAbstract:
Background: Pediatric occipital epileptiform discharges occur in various clinical settings, including self-limited and treatment-resistant epilepsies. The study objective is to determine electro-clinical predictors for prognosis in children with occipital epileptiform discharges. Methods: 205 patients with occipital epileptiform discharges were classified into seizure groups: self-limited occipital (SLO) (n = 57), including Panayiotopoulos and Gastaut syndrome; non-self-limited occipital (non-SLO) (n = 98), including various seizure etiologies; genetic-generalized (n = 18); febrile (n = 5); and no-seizure (n = 27) groups. Electro-clinical features of the SLO and non-SLO were compared, as this is of most clinical relevance. Results: The median age of seizure onset was 3 years (range: 0-19). Occipital epileptiform discharges with frontal/central positivity were present in both groups, but more common in the SLO than non-SLO groups; 21/57 (36.8%) and 19/98 (19.4%), respectively ( P < .022). However, when occipital epileptiform discharges with tangential dipoles ( P < .048) were accompanied by abnormal ictal eye movements ( P < .037), they were predictive of SLO epilepsy. Conclusions: In our cohort, occipital epileptiform discharges with tangential dipole detected by visual analysis and abnormal ictal eye movements were predictive of SLO epilepsy.
41
Muhammad, Noor, Hammad Muhammad Khan, Ayesha Jawaid, Mohsin Syed Ali Shah, Owais Muhammad Ali, Sayyed Mohsin Ali Shah, and Saria Saeed. "ETIOLOGY OF LIVER CIRRHOSIS IN DISTRICT BUNER, KHYBER PAKHTUNKHWA." Journal of Medical Sciences 28, no. 4 (December 31, 2020): 364–66. http://dx.doi.org/10.52764/jms.20.28.4.21.
Full textAbstract:
Objective:
The aim of our study was to determine the most common cause of liver cirrhosis in district Buner.
Methodology:
This was retrospective cross-sectional study. Data was collected from patient’s record register from January 2016 till December 2018. A total of 203 patients were included in this study. Data was collected and entered and analyzed in IBM SPSS 23.
Results:
Out of 203 cases, 135(66.5%) were males and 68 (33.5%) were females. The main cause of cirrhosis was HCV (n=163, 80.3%) and HBV (n=27, 13.3%). Cryptogenic cirrhosis occurred in 9 cases (4.4%) while others were only 1% (n=2). HCV was more positive in males (n=108, 66.25%) than in females (n=55, 33.7%), this was statistically significant with a p value .022.
Conclusion:
We conclude with our study that HCV is major cause of Liver Cirrhosis in our patients. HCV is more common in males than in females. Cirrhosis occurs most commonly in 4th, 5th and 6th decades of life after being infected with HBV and HCV.
Keywords: Liver cirrhosis, Hepatitis C virus, Hepatitis B virus, Pakistan.
42
Hazuda, Helen P., Qing Pan, Hermes Florez, José A. Luchsinger, Jill P. Crandall, Elizabeth M. Venditti, Sherita H. Golden, Andrea M. Kriska, and George A. Bray. "Association of Intensive Lifestyle and Metformin Interventions With Frailty in the Diabetes Prevention Program Outcomes Study." Journals of Gerontology: Series A 76, no. 5 (January 11, 2021): 929–36. http://dx.doi.org/10.1093/gerona/glaa295.
Full textAbstract:
Abstract Background Frailty is a geriatric syndrome of decreased physiologic reserve and resistance to stressors that results in increased vulnerability to adverse health outcomes with aging. Diabetes and hyperglycemia are established risk factors for frailty. We sought to examine whether the odds of frailty among individuals at high risk of diabetes randomized to treatment with intensive lifestyle (ILS), metformin, or placebo differed after long-term follow-up. Method The sample comprised participants in the Diabetes Prevention Program (DPP) clinical trial, who continued follow-up in the DPP Outcomes Study (DPPOS) and completed frailty assessments in DPPOS Years 8 (n = 2385) and 10 (n = 2289), approximately 12 and 14 years after DPP randomization. Frailty was classified using Fried Frailty Phenotype criteria. GEE models adjusting for visit year with repeated measures pooled for Years 8 and 10 were used to estimate pairwise odds ratios (ORs) between ILS, metformin, and placebo for the outcomes of frail and prefrail versus nonfrail. Results Frailty prevalence by treatment group was ILS = 3.0%, metformin = 5.4%, placebo = 5.7% at Year 8, and ILS = 3.6%, metformin = 5.3%, placebo = 5.4% at Year 10. Odds ratios (95% CI) estimated with GEE models were ILS versus placebo, 0.62 (0.42–0.93), p = .022; metformin versus placebo, 0.99 (0.69–1.42), p = .976; and ILS versus metformin, 0.63 (0.42–0.94), p = .022. Odds of being frail versus nonfrail were 37% lower for ILS compared to metformin and placebo. Conclusions Early ILS intervention, at an average age of about 50 years, in persons at high risk of diabetes may reduce frailty prevalence in later life. Metformin may be ineffective in reducing frailty prevalence. Clinical Trials Registration Numbers NCT00004992 (DPP) and NCT00038727 (DPPOS).
43
Neyns, Bart, Jeffrey S. Weber, Celeste Lebbé, Michele Maio, Kaan Harmankaya, Omid Hamid, Steven O'Day, et al. "Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 9059. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9059.
Full textAbstract:
9059 Background: Ipi is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte antigen-4 to augment antitumor immune responses. In phase III study MDX010-20, where patients (pts) could be retreated if they met safety criteria and achieved an objective response or stable disease ≥3 months from the end of the induction period (q3 weeks for 4 doses), 21 of 31 pts (68%) retreated with Ipi reestablished disease control. CA184-025 is a roll-over study of extended Ipi treatment or survival follow-up in pts who received Ipi in phase II trials, with the primary objective of evaluating safety during extended treatment. We report the safety profile in pts retreated with Ipi in study 025. Methods: Eligible pts in phase II trials CA184-004, -007, -008, -022, MDX010-08, or -015 were enrolled in study 025 (N=248) to receive retreatment (at the time of progression), extended maintenance (if no prior progression), or survival follow-up only. Pts were ineligible for retreatment if they had experienced a grade 3-4 non-skin toxicity during prior Ipi therapy. Ipi was administered at 10 mg/kg, q3 weeks for 4 doses, to 111 pts who initially received Ipi induction at 0.3, 3, or 10 mg/kg in a parent study. Results: In this selected population of eligible pts, the nature and frequency of immune-related adverse events (irAEs) during retreatment were similar to those reported in previous studies, which most commonly affected the GI tract and skin (Table). There were no new types of drug-related irAEs and no grade 5 irAEs upon retreatment. Conclusions: Retreatment with Ipi at 10 mg/kg in these pts was generally well tolerated and the safety profile was similar to that during induction dosing in the parent studies. The higher frequencies of irAEs at lower doses should be interpreted with caution given the small sample sizes. An ongoing, randomized phase II trial will evaluate the clinical benefit of Ipi retreatment. Clinical trial information: NCT00162123. [Table: see text]
44
Scher, Richard L., Wilfred Saito, Richard K. Dodge, William J. Richtsmeier, and Robert L. Fine. "Fenretinide-Induced Apoptosis of Human Head and Neck Squamous Carcinoma Cell Lines." Otolaryngology–Head and Neck Surgery 118, no. 4 (April 1998): 464–71. http://dx.doi.org/10.1177/019459989811800406.
Full textAbstract:
BACKGROUND: Squamous cell carcinoma of the head and neck (HNSCC) has a high incidence of recurrence and associated second primary malignancy. The retinoid 13- cis-retinoic acid has been shown to be effective as both a chemopreventive and chemotherapeutic agent for HNSCC, but often with treatment-limiting toxicity. The synthetic retinoid fenretinide (N-(4-hydroxyphenyl)retinamide) (HPR) has significant antiproliferative activity against a number of animal and human malignancies and has been used in clinical trials as a chemopreventive agent in patients with breast and prostate cancer and oral leukoplakia. HPR has been shown to have a toxicity profile lower than that for other retinoids used in clinical trials. PURPOSE: The aim of this study was to investigate the effect of HPR on the growth of HNSCC cell lines in vitro. METHODS: Four HNSCC cell lines (JHU-011-SCC, JHU-020-SCC, JHU-022-SCC, and FaDu) were treated with a range of concentrations of HPR for various times. After HPR exposure, cell viability was determined by tetrazolium dye (MTT) colorimetric assay, comparing cell survival with that of untreated control cells. HPR-induced apoptosis was determined by flow-cytometric deoxyribonucleic acid cell-cycle analysis, ultrastructural analysis with electron microscopy, and deoxyribonucleic acid fragmentation detected by gel electrophoresis. RESULTS: HPR caused significant growth inhibition in three of the four HNSCC cell lines in a dose- and time-dependent fashion. In two cell lines (JHU-011-SCC, JHU-020-SCC) a significant antiproliferative effect was achieved between 1 and 2.5 μ mol/L HPR after 72 hours of treatment. By deoxyribonucleic acid cell-cycle analysis, electron microscopy, and gel electrophoresis, HPR was shown to induce apoptosis in the JHU-011-SCC and JHU-020-SCC cell lines, but not in the FaDu cell line, which was insensitive to the growth inhibitory effect of HPR. CONCLUSIONS: This study has demonstrated that HPR reduces cell viability in HNSCC cells in vitro at clinically relevant doses, with the growth inhibition occurring through the induction of apoptosis.
45
Maio, Michele, Matteo Carlino, Anthony Joshua, Elaine McWhirter, Antoni Ribas, Paolo Ascierto, Wilson Miller, et al. "P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma." Journal for ImmunoTherapy of Cancer 8, Suppl 1 (April 2020): A10.2—A11. http://dx.doi.org/10.1136/lba2019.16.
Full textAbstract:
BackgroundPembrolizumab+dabrafenib+trametinib demonstrated promising antitumor activity and acceptable tolerability in BRAF-mutant melanoma in phase 1/2 KEYNOTE-022 parts 1 and 2 (NCT02130466). Pembrolizumab+dabrafenib+trametinib numerically prolonged PFS and DOR versus placebo+dabrafenib+trametinib but had a higher grade 3-5 TRAE rate in part 3. KEYNOTE-022 parts 4 and 5 evaluated pembrolizumab+trametinib.MethodsIn part 4 (open-label, 3+3 dose-finding) patients with advanced solid tumors (irrespective of BRAF status) or unresectable/metastatic BRAF wild-type melanoma received pembrolizumab 200 mg Q3W with trametinib as concurrent (2 or 4 weeks of trametinib run-in [1.5 or 2 mg QD], then pembrolizumab+trametinib [1.5 or 2 mg QD]) or intermittent dosing (2 weeks of trametinib run-in [1.5 or 2 mg QD], then pembrolizumab+trametinib [1.5 or 2 mg QD; 1 week off/2 weeks on]). Interim MTDs identified in part 4 were confirmed in part 5 using a modified toxicity probability interval design. The primary objectives were safety, tolerability, and ORR by investigator assessment per RECIST v1.1 of the maximum administered or tolerated dose (MAD/MTD) of pembrolizumab+trametinib. Safety was analyzed for all patients who received ≥1 dose of study drug; patients treated during the trametinib run-in who discontinued study before receiving pembrolizumab were included; patients who did not complete trametinib run-in or receive ≥66% of planned doses during the 6-week dose-limiting toxicity (DLT) evaluable period were not included for DLT evaluation. AEs were graded per NCI CTCAE v4.ResultsOf 42 enrolled patients, most were female (61.9%); median age was 55.0 years; 57.1% had received ≥2 prior lines of therapy. At database cutoff (June 26, 2019), median follow-up was 9.0 months (range, 1.4-25.6 months). Of 38 DLT-evaluable patients, 10 had DLTs (table 1). Dosing regimens were selected for confirmation in part 5 based on safety data. Any-grade TRAEs occurred in 39 (92.9%) patients; grade 3-4 TRAEs occurred in 19 (45.2%), none were grade 5. TRAEs led to discontinuation in 8 (19.0%) patients. Immune-mediated AEs occurred in 12 (28.6%) patients, most commonly severe skin reactions (n=6; 14.3%), pneumonitis (n=3; 7.1%), hypothyroidism (n=2; 4.8%). The MTD of concurrent pembrolizumab+trametinib was pembrolizumab 200 mg Q3W plus trametinib 1.5 mg with 2 weeks of trametinib run-in (ORR, 0/16; 0%) and the MTD of intermittent pembrolizumab+trametinib was pembrolizumab 200 mg Q3W plus trametinib 2 mg with 2 weeks of run-in (ORR, 4/15; 26.7%).Abstract P863 Table 1DLT, TRAE, and ORR in KEYNOTE-022 parts 4 and 5ConclusionsBoth concurrent or intermittent pembrolizumab+trametinib dosing were feasible and the combination showed antitumor activity in patients with advanced solid tumors or advanced BRAF wild-type melanoma.
46
Maggioni, Martina A., Matteo Bonato, Alexander Stahn, Antonio La Torre, Luca Agnello, Gianluca Vernillo, Carlo Castagna, and Giampiero Merati. "Effects of Ball Drills and Repeated-Sprint-Ability Training in Basketball Players." International Journal of Sports Physiology and Performance 14, no. 6 (July 1, 2019): 757–64. http://dx.doi.org/10.1123/ijspp.2018-0433.
Full textAbstract:
Purpose: To investigate the effects of ball drills and repeated-sprint-ability training during the regular season in basketball players. Methods: A total of 30 players were randomized into 3 groups: ball-drills training (BDT, n = 12, 4 × 4 min, 3 vs 3 with 3-min passive recovery), repeated-sprint-ability training (RSAT, n = 9, 3 × 6 × 20-m shuttle running with 20-s and 4-min recovery), and general basketball training (n = 9, basketball technical/tactical exercises), as control group. Players were tested before and after 8 wk of training using the following tests: , squat jump, countermovement jump, Yo-Yo Intermittent Recovery Test Level 1 (YIRT1), agility T test, line-drill test, 5-/10-/20-m sprints, and blood lactate concentration. A custom-developed survey was used to analyze players’ technical skills. Results: After training, significant improvements were seen in YIRT1 (BDT P = .014, effect size [ES] ± 90% CI = 0.8 ± 0.3; RSAT P = .022, ES ± 90% CI = 0.7 ± 0.3), the agility T test (BDT P = .018, ES ± 90% CI = 0.7 ± 0.5; RSAT P = .037, ES ± 90% CI = 0.7 ± 0.5), and the line-drill test (BDT P = .010, ES ± 90% CI = 0.3 ± 0.1; RSAT P < .0001, ES ± 90% CI = 0.4 ± 0.1). In the RSAT group, only 10-m sprint speeds (P = .039, ES ± 90% CI = 0.3 ± 0.2) and blood lactate concentration (P = .004, ES ± 90% CI = 0.8 ± 1.1) were improved. Finally, technical skills were increased in BDT regarding dribbling (P = .038, ES ± 90% CI = 0.8 ± 0.6), shooting (P = .036, ES ± 90% CI = 0.8 ± 0.8), passing (P = .034, ES ± 90% CI = 0.9 ± 0.3), rebounding (P = .023, ES ± 90% CI = 1.1 ± 0.3), defense (P = .042, ES ± 90% CI = 0.5 ± 0.5), and offense (P = .044, ES ± 90% CI = 0.4 ± 0.4) skills. Conclusions: BDT and RSAT are both effective in improving the physical performance of basketball players. BDT had also a positive impact on technical skills. Basketball strength and conditioning professionals should include BDT as a routine tool to improve technical skills and physical performance simultaneously throughout the regular training season.
47
Ramirez, Francisco E., Giorgia Maghelli, and Neil Nedley. "Depression is more severe among females with autoimmune conditions." Journal of Immunology 204, no. 1_Supplement (May 1, 2020): 58.1. http://dx.doi.org/10.4049/jimmunol.204.supp.58.1.
Full textAbstract:
Abstract Rationale We explore the relationship between severity of depression on participants with autoimmune conditions and its relationship with gender. Methods Participants from a non medical community educational program that finished the intervention and had an autoimmune condition were used in the study. Participants met once a week for 8 weeks for a 2-hour program, which educated them about healthy lifestyle habits like diet, exercise, control of thoughts, etc. Each patient took the Depression and Anxiety Assessment Test (DAAT registration TX 7-398-022) before and after the intervention. The questionnaire measured depression and asked about demographics, patient history and research consent. Results From n=5651 people that finished the intervention n=432 participants reported autoimmune disease and were used in the study, n=369 (85%) were female and n=64 (15%) were male. At baseline regarding depression severity, female participants n=116 (32%) reported severe depression, n=130 (35%) moderate, n=60 (16%) mild, and n=62 (17%) none. Male participants on the other hand reported n=63 (22%) severe depression, n=14 (29%) moderate, n=18 (30%) mild, and n=12 (19%) none. At the end of the program, females reported the depression reported in the group was n=22 (5.9%) severe depression, moderate n=94 (26%), mild n=61 (17%), and n=191 (52%) none. For males, end group depression distribution was n=4 (6.3%) severe depression, n=11 (17%) moderate, n=15 (24%) mild, and n=33 (52%) none. Conclusions More women with autoimmune disease seem to have more severe depression than men, but both genders improved at the end of the program. Further follow up is being planned.
48
Fedoruk, Hailey, Bergen Vetsch, Boshra Mandour, Bryan Lum, Randal Nelson, Kelly-Ann Leonard, Gia Shelp, Jessica Yue, and Rene Jacobs. "P11-022-23 Dietary Trimethylamine N-Oxide Supplementation Improves Insulin Sensitivity and Hepatic Glucose Metabolism in High-Fat Diet Fed Mice." Current Developments in Nutrition 7 (July 2023): 101819. http://dx.doi.org/10.1016/j.cdnut.2023.101819.
Full text
49
Hsu, Peter, James C. Gay, Chyongchiou J. Lin, Mark Rodeghier, Michael R. DeBaun, and Robert M. Cronin. "Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial." Blood Advances 5, no. 23 (December 3, 2021): 5032–40. http://dx.doi.org/10.1182/bloodadvances.2021004864.
Full textAbstract:
Abstract In 2020, the American Society of Hematology published evidence-based guidelines for cerebrovascular disease in individuals with sickle cell anemia (SCA). Although the guidelines were based on National Institutes of Health–sponsored randomized controlled trials, no cost-effectiveness analysis was completed for children with SCA and silent cerebral infarcts. We conducted a cost-effectiveness analysis comparing regular blood transfusion vs standard care using SIT (Silent Cerebral Infarct Transfusion) Trial participants. This analysis included a modified societal perspective with direct costs (hospitalization, emergency department visit, transfusion, outpatient care, and iron chelation) and indirect costs (special education). Direct medical costs were estimated from hospitalizations from SIT hospitals and unlinked aggregated hospital and outpatient costs from SIT sites by using the Pediatric Health Information System. Indirect costs were estimated from published literature. Effectiveness was prevention of infarct recurrence. An incremental cost-effectiveness ratio using a 3-year time horizon (mean SIT Trial participant follow-up) compared transfusion vs standard care. A total of 196 participants received transfusions (n = 90) or standard care (n = 106), with a mean age of 10.0 years. Annual hospitalization costs were reduced by 54% for transfusions vs standard care ($4929 vs $10 802), but transfusion group outpatient costs added $22 454 to $137 022 per year. Special education cost savings were $2634 over 3 years for every infarct prevented. Transfusion therapy had an incremental cost-effectiveness ratio of $22 025 per infarct prevented. Children with preexisting silent cerebral infarcts receiving blood transfusions had lower hospitalization costs but higher outpatient costs, primarily associated with the oral iron chelator deferasirox. Regular blood transfusion therapy is cost-effective for infarct recurrence in children with SCA. This trial is registered at www.clinicaltrials.gov as #NCT00072761.
50
Hsu, Peter, James C. Gay, Chyongchiou J. Lin, Mark Rodeghier, Michael R. DeBaun, and Robert M. Cronin. "Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial." Blood Advances 5, no. 23 (December 3, 2021): 5032–40. http://dx.doi.org/10.1182/bloodadvances.2021004864.
Full textAbstract:
Abstract In 2020, the American Society of Hematology published evidence-based guidelines for cerebrovascular disease in individuals with sickle cell anemia (SCA). Although the guidelines were based on National Institutes of Health–sponsored randomized controlled trials, no cost-effectiveness analysis was completed for children with SCA and silent cerebral infarcts. We conducted a cost-effectiveness analysis comparing regular blood transfusion vs standard care using SIT (Silent Cerebral Infarct Transfusion) Trial participants. This analysis included a modified societal perspective with direct costs (hospitalization, emergency department visit, transfusion, outpatient care, and iron chelation) and indirect costs (special education). Direct medical costs were estimated from hospitalizations from SIT hospitals and unlinked aggregated hospital and outpatient costs from SIT sites by using the Pediatric Health Information System. Indirect costs were estimated from published literature. Effectiveness was prevention of infarct recurrence. An incremental cost-effectiveness ratio using a 3-year time horizon (mean SIT Trial participant follow-up) compared transfusion vs standard care. A total of 196 participants received transfusions (n = 90) or standard care (n = 106), with a mean age of 10.0 years. Annual hospitalization costs were reduced by 54% for transfusions vs standard care ($4929 vs $10 802), but transfusion group outpatient costs added $22 454 to $137 022 per year. Special education cost savings were $2634 over 3 years for every infarct prevented. Transfusion therapy had an incremental cost-effectiveness ratio of $22 025 per infarct prevented. Children with preexisting silent cerebral infarcts receiving blood transfusions had lower hospitalization costs but higher outpatient costs, primarily associated with the oral iron chelator deferasirox. Regular blood transfusion therapy is cost-effective for infarct recurrence in children with SCA. This trial is registered at www.clinicaltrials.gov as #NCT00072761.